129 related articles for article (PubMed ID: 19794096)
1. A novel dasatinib-sensitive RCSD1-ABL1 fusion transcript in chemotherapy-refractory adult pre-B lymphoblastic leukemia with t(1;9)(q24;q34).
Mustjoki S; Hernesniemi S; Rauhala A; Kähkönen M; Almqvist A; Lundán T; Porkka K
Haematologica; 2009 Oct; 94(10):1469-71. PubMed ID: 19794096
[No Abstract] [Full Text] [Related]
2. RCSD1-ABL1-positive B lymphoblastic leukemia is sensitive to dexamethasone and tyrosine kinase inhibitors and rapidly evolves clonally by chromosomal translocations.
Inokuchi K; Wakita S; Hirakawa T; Tamai H; Yokose N; Yamaguchi H; Dan K
Int J Hematol; 2011 Sep; 94(3):255-260. PubMed ID: 21863287
[TBL] [Abstract][Full Text] [Related]
3. Relapse of BCR-ABL1-like ALL mediated by the ABL1 kinase domain mutation T315I following initial response to dasatinib treatment.
Yeung DT; Moulton DJ; Heatley SL; Nievergall E; Dang P; Braley J; Branford S; Moore S; Mullighan CG; Hughes TP; White DL
Leukemia; 2015 Jan; 29(1):230-2. PubMed ID: 25179732
[No Abstract] [Full Text] [Related]
4. Dasatinib and allogeneic stem cell transplantation enable sustained response in an elderly patient with
Frech M; Jehn LB; Stabla K; Mielke S; Steffen B; Einsele H; Metzelder SK; Neubauer A
Haematologica; 2017 Apr; 102(4):e160-e162. PubMed ID: 28057740
[No Abstract] [Full Text] [Related]
5. Acute lymphoblastic leukemia associated with RCSD1-ABL1 novel fusion gene has a distinct gene expression profile from BCR-ABL1 fusion.
De Braekeleer E; Douet-Guilbert N; Guardiola P; Rowe D; Mustjoki S; Zamecnikova A; Al Bahar S; Jaramillo G; Berthou C; Bown N; Porkka K; Ochoa C; De Braekeleer M
Leukemia; 2013 Jun; 27(6):1422-4. PubMed ID: 23168614
[No Abstract] [Full Text] [Related]
6. Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32).
De Keersmaecker K; Graux C; Odero MD; Mentens N; Somers R; Maertens J; Wlodarska I; Vandenberghe P; Hagemeijer A; Marynen P; Cools J
Blood; 2005 Jun; 105(12):4849-52. PubMed ID: 15713800
[TBL] [Abstract][Full Text] [Related]
7. A new partner gene fused to ABL1 in a t(1;9)(q24;q34)-associated B-cell acute lymphoblastic leukemia.
De Braekeleer E; Douet-Guilbert N; Le Bris MJ; Berthou C; Morel F; De Braekeleer M
Leukemia; 2007 Oct; 21(10):2220-1. PubMed ID: 17541395
[No Abstract] [Full Text] [Related]
8. [Pharmacological properties and clinical efficacy of dasatinib hydrate (Sprycel), an anticancer drug for chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia].
Fujii Y; Amano M; Seriu T
Nihon Yakurigaku Zasshi; 2009 Sep; 134(3):159-67. PubMed ID: 19749489
[No Abstract] [Full Text] [Related]
9. Molecular monitoring and mutation analysis of patients with advanced phase CML and Ph+ ALL receiving dasatinib.
Olsson-Strömberg U; Hermansson M; Lundán T; Ohm AC; Engdahl I; Höglund M; Simonsson B; Porkka K; Barbany G
Eur J Haematol; 2010 Nov; 85(5):399-404. PubMed ID: 20659155
[TBL] [Abstract][Full Text] [Related]
10. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study.
Ottmann O; Dombret H; Martinelli G; Simonsson B; Guilhot F; Larson RA; Rege-Cambrin G; Radich J; Hochhaus A; Apanovitch AM; Gollerkeri A; Coutre S
Blood; 2007 Oct; 110(7):2309-15. PubMed ID: 17496201
[TBL] [Abstract][Full Text] [Related]
11. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.
Soverini S; Colarossi S; Gnani A; Castagnetti F; Rosti G; Bosi C; Paolini S; Rondoni M; Piccaluga PP; Palandri F; Giannoulia P; Marzocchi G; Luatti S; Testoni N; Iacobucci I; Cilloni D; Saglio G; Baccarani M; Martinelli G
Haematologica; 2007 Mar; 92(3):401-4. PubMed ID: 17339191
[TBL] [Abstract][Full Text] [Related]
12. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
13. Can minor bcr/abl translocation in acute leukemia be discriminated from major bcr/abl by extra-signal FISH analysis?
Lee DS; Kim EC; Yoon BH; Kim WH; Yoon JH; Cho HI
Haematologica; 2001 Sep; 86(9):991-2. PubMed ID: 11532631
[No Abstract] [Full Text] [Related]
14. Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia.
Soverini S; Martinelli G; Colarossi S; Gnani A; Castagnetti F; Rosti G; Bosi C; Paolini S; Rondoni M; Piccaluga PP; Palandri F; Giannoulia P; Marzocchi G; Luatti S; Testoni N; Iacobucci I; Cilloni D; Saglio G; Baccarani M
J Clin Oncol; 2006 Nov; 24(33):e51-2. PubMed ID: 17114651
[No Abstract] [Full Text] [Related]
15. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Foà R; Vitale A; Vignetti M; Meloni G; Guarini A; De Propris MS; Elia L; Paoloni F; Fazi P; Cimino G; Nobile F; Ferrara F; Castagnola C; Sica S; Leoni P; Zuffa E; Fozza C; Luppi M; Candoni A; Iacobucci I; Soverini S; Mandelli F; Martinelli G; Baccarani M;
Blood; 2011 Dec; 118(25):6521-8. PubMed ID: 21931113
[TBL] [Abstract][Full Text] [Related]
16. Disappearance of both the BCR/ABL1 fusion gene and the JAK2V617F mutation with dasatinib therapy in a patient with imatinib-resistant chronic myelogenous leukemia.
Inokuchi K; Yamaguchi H; Tamai H; Dan K
J Clin Exp Hematop; 2012; 52(2):145-7. PubMed ID: 23037633
[No Abstract] [Full Text] [Related]
17. In vitro drug resistance to imatinib and mutation of ABL gene in childhood Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.
Kawaguchi H; Taketani T; Hongo T; Park MJ; Koh K; Ida K; Kobayashi M; Takita J; Taki T; Yoshino H; Bessho F; Hayashi Y
Leuk Lymphoma; 2005 Feb; 46(2):273-6. PubMed ID: 15621812
[TBL] [Abstract][Full Text] [Related]
18. TKI dasatinib monotherapy for a patient with Ph-like ALL bearing ATF7IP/PDGFRB translocation.
Kobayashi K; Miyagawa N; Mitsui K; Matsuoka M; Kojima Y; Takahashi H; Ootsubo K; Nagai J; Ueno H; Ishibashi T; Sultana S; Okada Y; Akimoto S; Okita H; Matsumoto K; Goto H; Kiyokawa N; Ohara A
Pediatr Blood Cancer; 2015 Jun; 62(6):1058-60. PubMed ID: 25400122
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of dasatinib in conjunction with alpha-interferon for the treatment of imatinib-resistant and dasatinib-resistant Ph+ acute lymphoblastic leukemia.
Visani G; Piccaluga P; Malagola M; Isidori A
Leukemia; 2009 Sep; 23(9):1687-8. PubMed ID: 19421228
[No Abstract] [Full Text] [Related]
20. Clonal evolution with +11q 13, t(1;7) and t(1;4) at relapse in a patient with Ph positive acute lymphocytic leukemia (ALL) treated with single agent front line imatinib followed by dasatinib.
Ramanarayanan J; Mehdi S; Brodzik F; Pasquale D
Hematology; 2007 Dec; 12(6):505-9. PubMed ID: 17852464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
